DALLAS, Oct. 21, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Inovio Biomedical Corp. (NYSE Amex:INO). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Inovio Biomedical Corp. (NYSE Amex:INO) should be of particular interest to other biotechnology companies: Gilead Sciences Inc. (Nasdaq:GILD), Biogen Idec Inc. (Nasdaq:BIIB), Genzyme Corp. (Nasdaq:GENZ) and Life Technologies Corp. (Nasdaq:LIFE).
It is available at: http://www.investorsoup.com/lp/INO
Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup
Inovio Biomedical Corp. (INO) is a San Diego-based biomedical company focused on the development of vaccines to prevent or treat cancers and chronic infectious diseases. The Company develops deoxyribonucleic acid (DNA) delivery solutions based on electroporation, which uses brief, controlled electrical pulses to create temporary pores in cell membranes and enable increased cellular uptake of a useful biopharmaceutical. Once the DNA vaccine enters a cell, it can then express the proteins it was encoded to produce.
In the report, the analyst notes:
"INO last week announced the initiation of a phase I clinical study of its PENNVAX-B preventive DNA vaccine delivered using the Company's proprietary electroporation technology. The multi-center study will be conducted at several HVTN clinical sites under a protocol designated HVTN-080. The study will enroll healthy volunteers to assess the safety of and immune responses to this DNA-based vaccine delivered via in vivo electroporation. The Company previously reported data from non-human primates demonstrating up to a 100-fold enhancement in immune responses resulting from the vaccine when delivered via in vivo electroporation compared to syringe injection without electroporation.
"INO announced earlier this month that a combination of its synthetic consensus (SynCon(TM)) H1N1 influenza vaccine candidates achieved protective antibody responses against the novel pandemic influenza A/H1N1 (2009) in 100% of tested ferrets. The ferret model is widely considered to be the most representative of human influenza; achieving in ferrets a level of antibody titers commonly associated with protection in humans is a critical milestone in influenza vaccine development."
To read the entire report visit: http://www.investorsoup.com/lp/INO
See what investors say about these stocks at: http://www.stockhideout.com/
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.